The Angiopoietin 1 Receptor pipeline drugs market research report outlays comprehensive information on the Angiopoietin 1 Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Angiopoietin 1 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Ophthalmology, Infectious Disease, and Genito Urinary System which include the indications Solid Tumor, Hepatocellular Carcinoma, Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Unspecified Influenza Virus Infections, Coronavirus Disease 2019 (COVID-19), Acute Renal Failure (ARF) (Acute Kidney Injury), and Chronic Kidney Disease (Chronic Renal Failure). It also reviews key players involved in Angiopoietin 1 Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Angiopoietin 1 Receptor pipeline targets constitutes close to 33 molecules. Out of which, approximately 30 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 5, 2, 1, 14, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 2 molecule.
Angiopoietin 1 Receptor overview
Angiopoietin-1 receptor or CD202B is a protein encoded by the TEK gene.It regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton. It also maintains of vascular quiescence. It has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. It is required for normal angiogenesis and heart development during embryogenesis. It is required for post-natal hematopoiesis.
For a complete picture of Angiopoietin 1 Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
